Ascendis Pharma A/S (NASDAQ:ASND) Receives $296.72 Consensus Target Price from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has been assigned a consensus rating of “Buy” from the eighteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $296.1176.

Several equities analysts have recently weighed in on the company. Bank of America increased their price target on Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Royal Bank Of Canada upped their price objective on Ascendis Pharma A/S from $275.00 to $280.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Barclays increased their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Morgan Stanley raised their target price on Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Finally, Weiss Ratings upgraded Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime acquired 400 shares of the stock in a transaction dated Tuesday, May 26th. The shares were purchased at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 40.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ASND. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S in the third quarter worth about $26,000. Arax Advisory Partners grew its stake in shares of Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG bought a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Ascendis Pharma A/S in the 4th quarter worth approximately $42,000. Finally, Global Retirement Partners LLC increased its holdings in Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares in the last quarter.

Ascendis Pharma A/S Trading Down 0.4%

Shares of ASND stock opened at $254.57 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12-month low of $186.05 and a 12-month high of $282.15. The stock has a market capitalization of $15.88 billion, a P/E ratio of 29.36 and a beta of 0.39. The firm’s 50 day moving average is $247.52 and its 200 day moving average is $236.89.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.